Clinical trials
Hemophagocytic Lymphohistiocytosis clinical trials
Below are recruiting hemophagocytic lymphohistiocytosis clinical trials, each written for real people, not researchers. We’re tracking 14 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06339177Recruiting
HLH study looking at immune system and genes
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
Bethesda, MarylandAges 18–120 - NCT05416307RecruitingPhase 2/Phase 3
ELA026 for secondary HLH after certain diagnostic findings
This study tests ELA026 (a new drug) in people with secondary HLH, a serious immune condition triggered by another illness or cause. It aims to see how well ELA026 works and how safe it is, using an open-label design where everyone knows they are getting the treatment.
Birmingham, AlabamaAges 6 years+ - NCT06135922RecruitingPhase 1
EBV-TCR-T cells for EBV-related HLH or infection
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
Beijing, Beijing MunicipalityAges 1–60 - NCT07525466RecruitingPhase 1/Phase 2
New drug combination for NK/T-cell lymphoma with immune complications
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
BeijingAges 18 years+ - NCT07424222RecruitingPhase 1
Ruxolitinib for a serious immune reaction after CAR T therapy
This trial tests a drug called ruxolitinib for a rare but serious condition called IEC-HS that can happen after CAR T cell treatment. The goal is to see if ruxolitinib can calm this overactive immune response.
Baltimore, MarylandAges 18–99 - NCT07488728Recruiting
Letermovir to prevent CMV in children after stem cell transplant
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06160791RecruitingPhase 2
Ruxolitinib with reduced chemo for HLH treatment
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
Irvine, CaliforniaAges 18 years+ - NCT05277272Recruiting
Registry study for children with HLH
This study is a disease registry that collects medical information from children who have hemophagocytic lymphohistiocytosis (HLH) or are suspected to have it. It helps doctors better understand HLH and how it affects patients over time.
Cincinnati, OhioAges Any age - NCT05898477Recruiting
Studying treatment responses in lymphoma-related HLH
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Birmingham, AlabamaAges Any age - NCT06585124Recruiting
Study of t cells in lymphoma patients with HLH
This study looks at specific immune cells (T cells) in people who have a rare condition called Hemophagocytic Lymphohistiocytosis (HLH) together with an aggressive lymphoma. It aims to better understand how these cells behave, which may lead to improved diagnosis or treatment.
Rome, LazioAges 18 years+ - NCT06614998Recruiting
Early warning screening for hemophagocytic lymphohistiocytosis
This study aims to create an early warning system to identify patients with hemophagocytic lymphohistiocytosis (HLH), a rare but serious immune overreaction. If you have certain infections, autoimmune diseases, or lymphoma, this screening could help detect HLH early.
Xuzhou, JiangsuAges Any age - NCT07270835RecruitingPhase 4
Zanubrutinib plus rituximab for HLH with B-cell lymphoma
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
Suzhou, JiangsuAges 14–80 - NCT07339345RecruitingPhase 2/Phase 3
Testing a combination therapy for hemophagocytic lymphohistiocytosis
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Beijing, Beijing MunicipalityAges 14–70 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age
Hear when a new Hemophagocytic Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hemophagocytic lymphohistiocytosis?
- Yes. Clin2 currently lists 14 recruiting hemophagocytic lymphohistiocytosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophagocytic lymphohistiocytosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophagocytic lymphohistiocytosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.